FDA Approves Calquence (acalabrutinib) for Adults with Mantle Cell Lymphoma

October 31, 2017 -- The U.S. Food and Drug Administration today granted accelerated approval to Calquence (acalabrutinib) for the treatment of adults with mantle cell lymphoma who have received at least one prior therapy. “Mantle cell lymphoma is...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news